http://www.newswire.ca/en/story/1561151/tweed-to-acquire-bedrocan-canada
TORONTO and SMITHS FALLS, ON, June 24, 2015 /CNW Telbec/ - Tweed Marijuana Inc. ("TMI" or "Tweed") (TSXV: TWD), operator of licensed cannabis producers Tweed Inc. and Tweed Farms Inc., and Bedrocan Cannabis Corp. ("Bedrocan Canada") (TSXV: BED) are pleased to announce that they have entered into a definitive arrangement agreement, pursuant to which TMI will acquire all of the issued and outstanding securities of Bedrocan Canada. TMI will be renamed at its annual meeting of shareholders to reflect its evolution as a multi-brand holding company. This acquisition marks the beginning of the structured evolution of the Canadian cannabis sector, and it is intended that TMI's portfolio of technologies, brands and geographies will continue to expand.
Tweed and Bedrocan Canada represent distinct market segments that appeal to different consumer needs. To meet market expansion demands, TMI will function as a holding company that is uniquely able to respond to these distinct voices, and will increase its ability to grow market share and diversify client acquisition. Specifically, the Bedrocan Canada brand will be sustained and further supported in establishing its leadership with the clinical and research communities. The Bedrocan Canada division, with its unique focus, will continue to operate separately, though in alignment with the other TMI operating divisions.
Tweed represents industry-leading consumer brand power and production capacity. TMI was the first publicly traded, federally regulated cannabis company in North America and has consistently maintained the largest market capitalization in the industry. Bedrocan Canada represents clinical, scientific and research strength, especially as it pertains to strain genetics and stability, advanced automation in cannabis production, and standardization of active pharmaceutical ingredients. With its Dutch licensor, Bedrocan Canada is the most experienced medical cannabis producer in the world. Uniting Tweed, Tweed Farms, and Bedrocan Canada under TMI creates the organization best positioned to meet diverse consumer needs, engage in clinical research, and build trust with health practitioners and medical regulators.
"We are bringing the two strongest brands in Canadian cannabis under one roof," said Bruce Linton, Chairman and CEO of Tweed. "We will continue to develop and grow the Tweed and Bedrocan Canada brands, focusing on rapidly increasing market penetration for our full line of products. Over 5,000 existing customers will now benefit from having access to products from two producers. For future patients and physicians, the choice will be clear."
"The rationale for and benefits of this transaction are clear, for investors, health professionals, researchers, and most importantly, for patients," said Marc Wayne, President and CEO of Bedrocan Canada. "Tweed and Bedrocan Canada have each helped set the industry standards for professionalism, product quality, dependable supply and exceptional customer care. Together, we will have the largest production and sales capacity in the industry, as well as a broad and complementary product line, and will be capable of allocating additional resources to product research and innovation, as well as to continuous improvement of the customer care experience."
The current consolidated licensed sales capacity of approximately 6,000 kg/yr will ensure that today's customers have access to a consistent supply of cannabis across a variety of product lines, with the potential to reach an even greater number of patients, pending further Health Canada approvals at TMI's three existing facilities. The company will continue to leverage its two state-of-the-art indoor facilities, as well as its greenhouse platform.
Under the terms of the acquisition, Bedrocan Canada shareholders will be entitled to receive 0.4650 common shares of TMI for each common share of Bedrocan Canada held. It is expected that TMI will issue a total of approximately 33.9 million common shares in connection with the acquisition having an aggregate value of approximately $61.0 million based on the $1.80 per share closing price of the TMI shares on the TSX Venture Exchange on June 23, 2015.
In connection with the acquisition, TMI will appoint two individuals designated by Bedrocan Canada to the board of directors of TMI. The acquisition is intended to be implemented by way of plan of arrangement and is currently expected to close by the end of August 2015. Closing remains subject to Bedrocan Canada shareholder approval, court approval, the approval of the TSX Venture Exchange, and an amendment to the terms of Bedrocan Canada's license agreement with Bedrocan Beheer BV, among other conditions precedent. Upon closing of the acquisition, Bedrocan Canada will become a subsidiary of TMI.
Additional details of the proposed transaction will be provided to Bedrocan shareholders in information circular to be delivered to them in connection with an upcoming special meeting of shareholders to be held to consider the proposed transaction. The Board of Directors of Bedrocan Canada intends to recommend unanimously that Bedrocan Canada shareholders vote in favour of the acquisition.
The recommendation of the Board of Directors of Bedrocan Canada is supported by a fairness opinion provided to its Special Committee by the Committee's financial advisor Dundee Securities Ltd., to the effect that the consideration is fair to Bedrocan Canada shareholders. PowerOne Capital Markets Limited also acted as a financial advisor to Bedrocan Canada in connection with the transaction. LaBarge Weinstein LLP acts as legal counsel to TMI and Cassels Brock & Blackwell acted as legal counsel to Bedrocan Canada in connection with the transaction. TMI has engaged GMP Securities L.P. to provide a fairness opinion to TMI in connection with the transaction.
TORONTO and SMITHS FALLS, ON, June 24, 2015 /CNW Telbec/ - Tweed Marijuana Inc. ("TMI" or "Tweed") (TSXV: TWD), operator of licensed cannabis producers Tweed Inc. and Tweed Farms Inc., and Bedrocan Cannabis Corp. ("Bedrocan Canada") (TSXV: BED) are pleased to announce that they have entered into a definitive arrangement agreement, pursuant to which TMI will acquire all of the issued and outstanding securities of Bedrocan Canada. TMI will be renamed at its annual meeting of shareholders to reflect its evolution as a multi-brand holding company. This acquisition marks the beginning of the structured evolution of the Canadian cannabis sector, and it is intended that TMI's portfolio of technologies, brands and geographies will continue to expand.
Tweed and Bedrocan Canada represent distinct market segments that appeal to different consumer needs. To meet market expansion demands, TMI will function as a holding company that is uniquely able to respond to these distinct voices, and will increase its ability to grow market share and diversify client acquisition. Specifically, the Bedrocan Canada brand will be sustained and further supported in establishing its leadership with the clinical and research communities. The Bedrocan Canada division, with its unique focus, will continue to operate separately, though in alignment with the other TMI operating divisions.
Tweed represents industry-leading consumer brand power and production capacity. TMI was the first publicly traded, federally regulated cannabis company in North America and has consistently maintained the largest market capitalization in the industry. Bedrocan Canada represents clinical, scientific and research strength, especially as it pertains to strain genetics and stability, advanced automation in cannabis production, and standardization of active pharmaceutical ingredients. With its Dutch licensor, Bedrocan Canada is the most experienced medical cannabis producer in the world. Uniting Tweed, Tweed Farms, and Bedrocan Canada under TMI creates the organization best positioned to meet diverse consumer needs, engage in clinical research, and build trust with health practitioners and medical regulators.
"We are bringing the two strongest brands in Canadian cannabis under one roof," said Bruce Linton, Chairman and CEO of Tweed. "We will continue to develop and grow the Tweed and Bedrocan Canada brands, focusing on rapidly increasing market penetration for our full line of products. Over 5,000 existing customers will now benefit from having access to products from two producers. For future patients and physicians, the choice will be clear."
"The rationale for and benefits of this transaction are clear, for investors, health professionals, researchers, and most importantly, for patients," said Marc Wayne, President and CEO of Bedrocan Canada. "Tweed and Bedrocan Canada have each helped set the industry standards for professionalism, product quality, dependable supply and exceptional customer care. Together, we will have the largest production and sales capacity in the industry, as well as a broad and complementary product line, and will be capable of allocating additional resources to product research and innovation, as well as to continuous improvement of the customer care experience."
The current consolidated licensed sales capacity of approximately 6,000 kg/yr will ensure that today's customers have access to a consistent supply of cannabis across a variety of product lines, with the potential to reach an even greater number of patients, pending further Health Canada approvals at TMI's three existing facilities. The company will continue to leverage its two state-of-the-art indoor facilities, as well as its greenhouse platform.
Under the terms of the acquisition, Bedrocan Canada shareholders will be entitled to receive 0.4650 common shares of TMI for each common share of Bedrocan Canada held. It is expected that TMI will issue a total of approximately 33.9 million common shares in connection with the acquisition having an aggregate value of approximately $61.0 million based on the $1.80 per share closing price of the TMI shares on the TSX Venture Exchange on June 23, 2015.
In connection with the acquisition, TMI will appoint two individuals designated by Bedrocan Canada to the board of directors of TMI. The acquisition is intended to be implemented by way of plan of arrangement and is currently expected to close by the end of August 2015. Closing remains subject to Bedrocan Canada shareholder approval, court approval, the approval of the TSX Venture Exchange, and an amendment to the terms of Bedrocan Canada's license agreement with Bedrocan Beheer BV, among other conditions precedent. Upon closing of the acquisition, Bedrocan Canada will become a subsidiary of TMI.
Additional details of the proposed transaction will be provided to Bedrocan shareholders in information circular to be delivered to them in connection with an upcoming special meeting of shareholders to be held to consider the proposed transaction. The Board of Directors of Bedrocan Canada intends to recommend unanimously that Bedrocan Canada shareholders vote in favour of the acquisition.
The recommendation of the Board of Directors of Bedrocan Canada is supported by a fairness opinion provided to its Special Committee by the Committee's financial advisor Dundee Securities Ltd., to the effect that the consideration is fair to Bedrocan Canada shareholders. PowerOne Capital Markets Limited also acted as a financial advisor to Bedrocan Canada in connection with the transaction. LaBarge Weinstein LLP acts as legal counsel to TMI and Cassels Brock & Blackwell acted as legal counsel to Bedrocan Canada in connection with the transaction. TMI has engaged GMP Securities L.P. to provide a fairness opinion to TMI in connection with the transaction.
